{"id":723979,"date":"2024-12-11T06:56:01","date_gmt":"2024-12-11T06:56:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=723979"},"modified":"2024-12-11T06:56:01","modified_gmt":"2024-12-11T06:56:01","slug":"ascites-treatment-market-2034-ema-pdma-fda-approvals-medication-prevalence-therapies-clinical-trials-and-companies-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/ascites-treatment-market-2034-ema-pdma-fda-approvals-medication-prevalence-therapies-clinical-trials-and-companies-by-delveinsight_723979.html","title":{"rendered":"Ascites Treatment Market 2034: EMA, PDMA, FDA Approvals, Medication, Prevalence, Therapies, Clinical Trials and Companies by DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1733761580.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Ascites Treatment Market 2034: EMA, PDMA, FDA Approvals, Medication, Prevalence, Therapies, Clinical Trials and Companies by DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1733761580.jpeg\" alt=\"Ascites Treatment Market 2034: EMA, PDMA, FDA Approvals, Medication, Prevalence, Therapies, Clinical Trials and Companies by DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Ascites Treatment Market<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">Ascites Companies are Grifols Therapeutics LLC, Sanofi, Regeneron Pharmaceuticals, Sequana Medical N.V, Protgen Ltd, Healthgen Biotechnology Corp, Sichuan Clover Biopharmaceuticals Inc, Movetis, BioVie Inc., Ocelot Bio Inc, Novartis, and others.<\/div>\n<p style=\"text-align: justify;\">(Albany, USA) &nbsp;&nbsp;DelveInsight&#8217;s&nbsp;<strong>&ldquo;Ascites Market Insights, Epidemiology and Market Forecast &ndash; 2034&rdquo;&nbsp;<\/strong>report delivers an in-depth understanding of the Ascites, historical and forecasted epidemiology as well as the Ascites market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.<\/p>\n<p style=\"text-align: justify;\">Ascites Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Ascites Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Unlock detailed insights into the Ascites Market by downloading the comprehensive report from DelveInsight @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/ascites-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">Ascites Treatment Market Size<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the Ascites Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>In September 2024:- Versantis AG- A Phase 2a, Open-label, Randomized, Controlled, Multi-Center Study to Assess the Efficacy, Safety and Tolerability of VS-01 on Top of Standard of Care (SOC), Compared to SOC Alone, in Adult Patients With Acute-on-Chronic Liver Failure (ACLF) Grades 1 and 2 and Ascites.<\/li>\n<li>It is estimated that the Ascites treatment market will experience significant changes during the forecast period of 2024&ndash;2034, owing to the launch of new therapies that are in clinical development.<\/li>\n<li>DelveInsight analysis indicates that in 2023, the US had approximately 153 thousand cases of Ascites due to Cirrhosis, accounting for the largest share in the 7MM.<\/li>\n<li>DelveInsight&#8217;s analysis revealed that in Japan during 2023, there were 5,355 instances of Grade I ascites attributed to cirrhosis. Additionally, more severe cases of Grade II and III ascites were recorded at 24,394 cases each in the same year.<\/li>\n<li>The leading Ascites Companies such as&nbsp;<strong>Grifols Therapeutics LLC, Sanofi, Regeneron Pharmaceuticals, Sequana Medical N.V, Protgen Ltd, Healthgen Biotechnology Corp, Sichuan Clover Biopharmaceuticals Inc, Movetis, BioVie Inc., Ocelot Bio Inc, Novartis<\/strong>, and others.<\/li>\n<li>Promising Ascites Therapies such as&nbsp;<strong>Recombinant Human Serum Albumin, M701, paracentesis, OrsHSA, VS-01, Ambrisentan, Terlipressin,<\/strong>&nbsp;and others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Gain a competitive edge in the Ascites Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/ascites-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">Ascites Treatment Drugs<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Ascites Epidemiology Segmentation in the 7MM<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Number of Ascites Cases by Malignancies<\/li>\n<li>Number of Ascites Cases due to Cirrhosis<\/li>\n<li>Severity-specific Cases of Ascites due to Cirrhosis<\/li>\n<li>Refractory Ascites Patients with Cirrhosis<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Ascites Treatment Market Landscape<\/strong><\/p>\n<p style=\"text-align: justify;\">The treatment landscape of ascites due to cirrhosis include diuretics, paracentesis, insertion of a transjugular intrahepatic portosystemic shunt (TIPS), as well as managing complications to ascites such as spontaneous bacterial peritonitis (SBP). Mild and moderate ascites due to liver cirrhosis can be treated with dietary sodium restriction, treatment of the underlying disorder, fluid restriction, use of diuretics, and use of therapeutic paracentesis.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Discover key developments and opportunities in the Ascites Market. Click here to learn more from DelveInsight&rsquo;s latest report @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/ascites-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">Ascites Market Size<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Ascites Drugs Market<\/strong><\/p>\n<p style=\"text-align: justify;\">The Ascites market for drugs targeting ascites is notably constrained. While certain treatments provide symptomatic relief, there is a significant lack of approved drugs addressing the condition&#8217;s underlying causes. This scarcity of targeted treatments reflects a major challenge in effectively managing the diverse manifestations of ascites, indicating a substantial need for innovative solutions and advancements in drug development for more comprehensive care.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Ascites Emerging Drugs Profile<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>OCE-205: Ocelot Bio<\/li>\n<li>BIV201 (terlipressin): Biovie<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download DelveInsight&rsquo;s Ascites Market report today and stay ahead in this rapidly evolving field. @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/ascites-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">Ascites Clinical Trials<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Ascites Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Coverage- 7MM<\/li>\n<li>Ascites Companies- as Grifols Therapeutics LLC, Sanofi, Regeneron Pharmaceuticals, Sequana Medical N.V, Protgen Ltd, Healthgen Biotechnology Corp, Sichuan Clover Biopharmaceuticals Inc, Movetis, BioVie Inc., Ocelot Bio Inc, Novartis, and others.<\/li>\n<li>Ascites Therapies- Recombinant Human Serum Albumin, M701, paracentesis, OrsHSA, VS-01, Ambrisentan, Terlipressin, and others.<\/li>\n<li>Ascites Competitive Intelligence Analysis: SWOT analysis and Market entry strategies<\/li>\n<li>Ascites Unmet Needs, KOL&#8217;s views, Analyst&#8217;s views, Ascites Market Access and Reimbursement<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download the report to understand which factors are driving Ascites Market Trends @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/ascites-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">Ascites Market Trends<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Key Insights<\/p>\n<p style=\"text-align: justify;\">2. Report Introduction<\/p>\n<p style=\"text-align: justify;\">3. Executive Summary<\/p>\n<p style=\"text-align: justify;\">4. Ascites Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5 Key Events<\/p>\n<p style=\"text-align: justify;\">6 Epidemiology and Market Forecast Methodology<\/p>\n<p style=\"text-align: justify;\">7 Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">8 Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">9 Patient Journey<\/p>\n<p style=\"text-align: justify;\">10 Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">11 Ascites: Seven Major Market Analysis<\/p>\n<p style=\"text-align: justify;\">12 Unmet Needs<\/p>\n<p style=\"text-align: justify;\">13 SWOT Analysis<\/p>\n<p style=\"text-align: justify;\">14 KOL Views<\/p>\n<p style=\"text-align: justify;\">15 Market Access and Reimbursement<\/p>\n<p style=\"text-align: justify;\">16 Appendix<\/p>\n<p style=\"text-align: justify;\">17 DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">18 Disclaimer<\/p>\n<p style=\"text-align: justify;\">19 About DelveInsight<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About Us<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=ascites-treatment-market-2034-ema-pdma-fda-approvals-medication-prevalence-therapies-clinical-trials-and-companies-by-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +14699457679<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/primary-research-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/primary-research-services<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=ascites-treatment-market-2034-ema-pdma-fda-approvals-medication-prevalence-therapies-clinical-trials-and-companies-by-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Ascites Treatment Market Ascites Companies are Grifols Therapeutics LLC, Sanofi, Regeneron Pharmaceuticals, Sequana Medical N.V, Protgen Ltd, Healthgen Biotechnology Corp, Sichuan Clover Biopharmaceuticals Inc, Movetis, BioVie Inc., Ocelot Bio Inc, Novartis, and others. (Albany, USA) &nbsp;&nbsp;DelveInsight&#8217;s&nbsp;&ldquo;Ascites Market Insights, Epidemiology and &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/ascites-treatment-market-2034-ema-pdma-fda-approvals-medication-prevalence-therapies-clinical-trials-and-companies-by-delveinsight_723979.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,413],"tags":[],"class_list":["post-723979","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/723979","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=723979"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/723979\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=723979"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=723979"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=723979"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}